Filing Flows › Celularity (CELU) › Q1 2026 › vs Q1 2025
Celularity (CELU) Q1 2026 vs Q1 2025 (year over year)
Celularity's revenue fell $7.6M (-66%) from $11.4M in Q1 2025 to $3.8M in Q1 2026. The biggest changes: Product −$8.2M (-90%); License Royalty and Other +$730K (+73%); Service −$158K (-11%).
Celularity, Q1 2026: revenue $3.8M (-66% year over year), operating margin -263.5%, net earnings $874K, operating cash flow $1.4M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| License Royalty and Other | $1.7M | $1.0M | $730K | +73% |
| Service | $1.2M | $1.4M | −$158K | -11% |
| Product | $866K | $9.0M | −$8.2M | -90% |
| Revenue | $3.8M | $11.4M | −$7.6M | -66% |
| Other income, net | $11.0M | −$9.3M | $20.3M | — |
| Costs & expenses | $14.9M | $31.2M | −$16.3M | -52% |
| Operating costs | $14.0M | $21.9M | −$7.9M | -36% |
| Net earnings | $874K | −$19.8M | $20.6M | — |
| Cost of revenue | $1.5M | $3.6M | −$2.1M | -59% |
| Research & development | $3.0M | $3.7M | −$734K | -20% |
| SG&A | $9.2M | $14.3M | −$5.1M | -36% |
| Other operating costs | $368K | $368K | $0 | 0% |
| Operating cash sources | $3.7M | −$15.3M | $19.0M | — |
| Depreciation & amortization | $1.6M | $1.8M | −$237K | -13% |
| Share-based compensation | $1.2M | $2.6M | −$1.4M | -53% |
| Working capital & other | $2.3M | −$12.3M | $14.6M | — |
| Operating cash flow | $1.4M | −$3.0M | $4.4M | — |
Questions
How much did Celularity's revenue grow year over year in Q1 2026?
Celularity's revenue fell $7.6M (-66%) from $11.4M in Q1 2025 to $3.8M in Q1 2026.
What drove Celularity's revenue change in Q1 2026?
Product −$8.2M (-90%); License Royalty and Other +$730K (+73%); Service −$158K (-11%).